Vixarelimab
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Vixarelimab
- DrugBank Accession Number
- DB16350
- Background
Vixarelimab is under investigation in clinical trial NCT03816891 (A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Prurigo Nodularis).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Immunoglobulin g (234-proline,303-glutamine), anti-(human oncostatin m receptor subunit .beta.) (human monoclonal kpl-716 .gamma.-chain), disulfide with human monoclonal kpl-716 .lambda.-chain, dimer
- Vixarelimab
- External IDs
- 30C6 (N73D) IGG4P.AGLY/IGG1
- BIIB-069
- BIIB069
- KPL-716
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- W25GO3A75W
- CAS number
- 2243320-83-2
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Chronic Idiopathic Pruritus / Chronic Idiopathic Urticaria / Lichen Planus (LP) / Lichen simplex chronicus / Psoriasis Vulgaris (Plaque Psoriasis) 1 2 Completed Treatment Prurigo Nodularis / Pruritus 1 2 Recruiting Treatment Idiopathic Pulmonary Fibrosis (IPF) / Systemic Sclerosis With Lung Involvement 1 2 Recruiting Treatment Ulcerative Colitis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 15, 2020 20:03 / Updated at February 21, 2021 18:55